Ligand Pharmaceuticals logo

Ligand Pharmaceuticals

LGND | NASDAQ
Chart Builder DCF Calculator
$290.07
+$6.58 (+2.32%)
At close: Sep 21, 2026, 4:00 PM ET
$293.40
+$3.33 (+1.15%)
Pre-market: Sep 22, 2026, 4:54 AM ET

Market Data

Market Cap
$5.81B
Enterprise Value
$5.23B
Beta
0.98
Average Volume
313.68K
Shares Outstanding (Diluted)
21.84M
Shares Change YoY
9.59%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US53220K5048

Price Performance

Price Change 1M
1.3%
Price Change 3M
3.8%
Price Change 6M
41.8%
Price Change YTD
52.6%
Price Change 1Y
69.9%
Price Change 3Y
391.0%
Price Change 5Y
234.1%
1M CAGR (ann.)
-1.1%
1Y CAGR (ann.)
70.8%
5Y CAGR (ann.)
28.4%
All-Time CAGR
12.0%

Valuation

PE Ratio
31.02
Forward PE
23.35
PEG Ratio
0.03
Forward PEG
0.96
PS Ratio
20.01
Forward PS
15.10
PB Ratio
6.01
P/FCF Ratio
44.25
P/Adj. FCF Ratio
74.43
P/OCF Ratio
44.22
EV/Sales
18.00
EV/EBIT
21.82
EV/EBITDA
19.11
EV/FCF
39.82
Earnings Yield
3.2%
FCF Yield
2.3%
Adj. FCF Yield
1.3%

Financial Health

Net Cash
$582.22M
Total Debt
$1.13B
Cash & Short-Term Investments
$1.36B
Total Assets
$2.19B
Current Ratio
31.18
Quick Ratio
30.96
Debt / Equity Ratio
1.17
Debt / EBITDA
4.12
Debt / FCF
8.58
OCF / Debt
0.12
Interest Coverage
16.31
Altman Z-Score
4.51
Piotroski F-Score
5

Margins & Profitability

Gross Profit Margin
98.6%
Operating Profit Margin
34.7%
EBITDA Margin
94.2%
Net Profit Margin
67.9%
FCF Margin
45.2%
Adj. FCF Margin
26.9%
SBC / Revenue
18.3%
SBC Impact (per share)
-40.6%

Returns

Return on Assets
9.0%
Return on Equity
20.1%
Return on Invested Capital
3.9%
Return on Capital Employed
4.7%
Return on Tangible Assets
10.5%

Historical Growth (CAGR)

Revenue CAGR 3Y
22.9%
Revenue CAGR 5Y
2.9%
Revenue CAGR 10Y
12.7%
EPS CAGR 3Y
86.6%
EPS CAGR 5Y
27.6%
EPS CAGR 10Y
-0.3%
FCF CAGR 3Y
10.3%
FCF CAGR 5Y
34.6%
FCF CAGR 10Y
20.6%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
18
EPS Growth Next 3Y
17.8%
Revenue Growth Next 3Y
23.8%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
$2.28
EPS Growth Est (next Q)
-26.2%
Revenue Est (next Q)
$78.09M
Revenue Growth Est (next Q)
-32.4%

Fair Value Estimates

Graham Number
$100.72
Graham Upside
-65.3%
Lynch Fair Value
$233.75
Lynch Upside
-19.4%
Price Target
$338.50
Price Target Upside
16.7%

Cash Flow

Operating Cash Flow
$131.64M
Free Cash Flow
$131.37M
Adj. Free Cash Flow
$78.1M
FCF Per Share
$6.55
OCF Per Share
$6.56
OCF/S Ratio
45.3%

Income Statement

Revenue
$290.54M
Gross Profit
$289.64M
Operating Income
$100.93M
EBITDA
$273.74M
Net Income
$197.22M
EPS (Diluted)
$9.35
Revenue / Employee
$6.18M
Profit / Employee
$4.2M
Employees
47

© 2026 bestshares.com. All rights reserved.